Aquestive (AQST) Q3 2026 Earnings Call Transcript

Aquestive (AQST) reported Q3 2026 earnings, highlighting progress on key milestones. The company resubmitted its ANNAFILM application, outlicensed Libervant, and refinanced debt. It expects over $70M in cash by year-end. ANNAFILM's FDA review is ongoing with a decision expected by March 16, 2027. The company is preparing for a potential US launch and expanding into Canada and Europe. AQST also discussed its pipeline and financial discipline.

Original reporting
Published Nov 4, 2026, 5:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 4, 2026, 5:16 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Aquestive (AQST) Q3 2026 Earnings Call Transcript — source image
Decision brief

The 30-second read

$AQSTNeutralLow
01

Why it matters

Guidance updates provide modest new information but lack quantitative earnings surprises, limiting immediate trading impact.

02

Market read

The call offers incremental updates on cash and FDA timelines, relevant for biotech investors monitoring pipeline risk.

03

What to watch

Potential competitive pressure from auto‑injector products and payer reimbursement uncertainties.

Relevance 5/10Novelty 5/10Timing: post-earnings call

Background

Aquestive Therapeutics discussed its pipeline progress, cash position, and upcoming regulatory milestones during its Q3 2026 earnings call.

Company-level read

Ticker impact

$AQSTNeutralMedium confidence
Context

The earnings call disclosed updated cash guidance above $70M and a target FDA decision date of March 16, 2027 for Annamil.

Expected impact

potential modest upside if FDA approval occurs before the projected date; downside risk if delays persist

Evidence & confidence

Guidance is incremental and does not contain new financial results; impact hinges on regulatory outcome.

Market effects

Reinforces outlook for the allergy epinephrine market and may influence peer biotech valuations.

US biotech sector sees modest attention; no broader regional effect.

Limited to investors tracking FDA pipeline milestones.

Counterpoint

If FDA delays beyond March 2027, the stock could face pressure despite cash guidance.

Key entities

  • Aquestive Therapeutics

    Biopharma developing epinephrine delivery products.

  • Eton Pharmaceuticals

    Licensee for Libervant diazepam buccal film.

Related articles

$AQSTMed

Aquestive Therapeutics Eyes Needle-Free Allergy Treatment Launch Ahead of 2027 FDA Decision

Aquestive Therapeutics (AQST) presented data on Anaphylm, a needle-free allergy treatment, showing faster absorption and higher blood pressure changes than EpiPen. The company expects FDA decision by 2027 and projects a $2B U.S. market by 2029. AQST plans to launch in Canada, Europe, and the U.K. in 2024. The company also discussed its sales strategy and pipeline, including Libervant and AQST-108.

$AQSTMed

Aquestive Therapeutics, Inc. Q3 2026 Earnings Call Summary

Aquestive Therapeutics reported Q3 2026 earnings, highlighting milestones like the NDA resubmission for Annamil and out-licensing of Libervant. Revenue grew 14% year-to-date due to increased license and royalty income. The company plans a spring 2027 launch for Annamil, with $95M in contingent funding available. Management expects to end 2026 with over $70M in cash. The Libervant deal provided a $10M upfront payment, with potential for $47.5M in milestones.

$AQSTMed

Aquestive Therapeutics Reports Third Quarter 2026 Financial Results

Aquestive Therapeutics, Inc. (AQST) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Aquestive Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update • Anaphylm resubmission accepted with PDUFA goal date of March 16, 2027 • Anaphylm would be the first and only oral rescue medication for the treatment of severe allergic

$AQSTHigh

A dissolving film could become the first oral rescue medicine for severe allergies.

Aquestive Therapeutics (AQST) announced its Q3 2026 financial results and provided updates on its pipeline. The FDA accepted the resubmission of Anaphylm, an oral epinephrine product for severe allergies, with a PDUFA goal date of March 16, 2027. If approved, Anaphylm would be the first oral rescue medication for anaphylaxis. The company is also progressing with commercial preparations and international filings.

$AQSTMed

H.C. Wainwright reiterates Aquestive stock rating on FDA review

H.C. Wainwright reiterated a Buy rating and $10 price target for Aquestive Therapeutics (AQST) after the FDA accepted its drug candidate resubmission. AQST shares are down 15% this week but analysts see undervaluation. The company reported Q2 revenue of $13.82M, up 38% YoY, but a wider loss per share than expected. Cantor Fitzgerald also reiterated an Overweight rating with an $11 target.